Category: Synairgen

  • Synairgen starts dosing inhaled COVID-19 drug in phase 3 trial

    UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after encouraging topline results from a phase 2 study that started last March. The inhaled formulation of interferon beta-1a – delivered using a nebuliser – will be tested in 610 hospitalised COVID-19 patients who require supplemental oxygen in […]

  • Synairgen’s inhaled drug cuts chances of COVID-19 progressing

    An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease.  Southampton-based Synairgen said in a preliminary trial readout that the company’s SNG001 – an inhaled formulation of interferon beta – reduced risk of progression from “requiring oxygen” to ventilation by 79%.  The double-blind placebo-controlled […]